SCHEMBL3570293

SCHEMBL3570293

NC(=O)N(c1ccc(Cl)cc1)C(C(=O)Nc1ccc(-c2cc[n+]([O-])cc2)cc1)c1ccccc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
ALDH1A1 P00352 3/20 0.34
MAPT P10636 3/20 0.34
KDM4E B2RXH2 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
THRB P10828 1/20 0.34
CNR1 P21554 5/20 0.34
CNR2 P34972 1/20 0.34
UTS2R Q9UKP6 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
ROCK2 O75116 1/20 0.33
NPC1 O15118 2/20 0.33
ALOX15 P16050 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559162 0.89 PCTP (0.35) GAAMEN1KMT2AATMGPR55
SCHEMBL3570079 0.89 GAA (0.36) GAAMEN1KMT2AATMGPR55
SCHEMBL3557259 0.87 HDAC4 (0.44) GAAMEN1KMT2AATMGPR55
SCHEMBL3570559 0.80 F10 (0.41) GAAMEN1KMT2AATMGPR55
SCHEMBL3570181 0.80 MEN1 (0.36) GAAMEN1KMT2AALDH1A1MAPT
SCHEMBL3564016 0.79 F10 (0.41) GAAMEN1KMT2AALDH1A1MAPT
SCHEMBL3560098 0.79 PCTP (0.41) GAAMEN1KMT2AATMGPR55
SCHEMBL3557408 0.78 PCTP (0.35) GAAMEN1KMT2AATMGPR55
SCHEMBL3562244 0.78 PCTP (0.35) GAAMEN1KMT2AATMGPR55
SCHEMBL3568267 0.78 PCTP (0.35) GAAMEN1KMT2AATMGPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 GAA 495/4885MEN1 2311/4885KMT2A 4014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.